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Abstract
Lactobacillus rhamnosus strains are ubiquitous in fermented foods, and in the human body
where they are commensals naturally present in the normal microbiota composition of gut,
vagina and skin. However, in some cases, Lactobacillus spp. have been implicated in bac-
teremia. The aim of the study was to examine the genomic and immunological properties of
16 clinical blood isolates of L. rhamnosus and to compare them to the well-studied L. rham-
nosus probiotic strain GG. Blood cultures from bacteremic patients were collected at the
Helsinki University Hospital laboratory in 2005–2011 and L. rhamnosus strains were iso-
lated and characterized by genomic sequencing. The capacity of the L. rhamnosus strains
to activate serum complement was studied using immunological assays for complement
factor C3a and the terminal pathway complement complex (TCC). Binding of complement
regulators factor H and C4bp was also determined using radioligand assays. Furthermore,
the isolated strains were evaluated for their ability to aggregate platelets and to form biofilms
in vitro. Genomic comparison between the clinical L. rhamnosus strains showed them to be
clearly different from L. rhamnosus GG and to cluster in two distinct lineages. All L. rhamno-
sus strains activated complement in serum and none of them bound complement regulators.
Four out of 16 clinical blood isolates induced platelet aggregation and/or formed more bio-
films than L. rhamnosus GG, which did not display platelet aggregation activity nor showed
strong biofilm formation. These findings suggest that clinical L. rhamnosus isolates show
considerable heterogeneity but are clearly different from L. rhamnosus GG at the genomic
level. All L. rhamnosus strains are still normally recognized by the human complement
system.
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Introduction
Lactobacilli are Gram-positive, microaerophilic, or facultative anaerobic rods [1] that are com-
monly distributed in the environment, animals and humans [2]. In human, lactobacilli live as
commensals in the oral, gastrointestinal and female genital tracts [3]. An isolate from the
human intestinal tract, Lactobacillus rhamnosus strain GG (ATCC 53103) is a widely used and
well-characterized probiotic strain [4] which has been suggested to have health-promoting
effects including the prevention and treatment of gastro-intestinal infections and diarrhea and
stimulation of immune responses to prevent allergic symptoms [5].
Although no virulence traits have been described for Lactobacilli and their safety for use in
food products has been established [6], several Lactobacillus spp. have been isolated from
infected tissues, such as peritonitis [7, 8], endocarditis [9], pneumonia [10], deep abdominal
abscesses [11] and blood [9, 12]. The most commonly isolated Lactobacillus spp. from bacter-
emia include L. rhamnosus and L. casei, which are often used as probiotics [9]. Risk factors
associated with Lactobacillus bacteremia consist of weakened host defences and serious under-
lying disease [13]. The symptoms of clinical study cases suffering from Lactobacillus-associated
bacteremia can vary from asymptomatic to severe septicemia [9]. It has raised a question
whether these isolates have developed any properties found from pathogenic bacteria such as
group A streptococci (S. pyogenes), which have evolved multiple mechanisms to adapt, survive
and grow in the human body [14]. Some of these features have been characterized in studies
with different Lactobacillus strains isolated from blood or infected tissues. L. rhamnosus and L.
salivarius strains but not L. rhamnosus GG have been found to induce platelet aggregation
[15–19]. L. rhamnosus strains isolated from blood have been shown to have differences in
binding to mucus, collagen and fibrinogen and in survival in serum when compared to L.
rhamnosus GG [20]. Two Lactobacillus rhamnosus clinical isolates from dental pulp infection
were found to have a modified exopolysaccharide (EPS) cluster which was different from L.
rhamnosus GG [21].
It has not been demonstrated unequivocally whether the isolated L. rhamnosus strains from
infected tissue or blood of bacteremic patients were similar to L. rhamnosus GG at genomic
level and whether they have similar or distinct features with L. rhamnosus GG in terms of
immunological and immunogenic properties in the human host. This has now become possi-
ble since the complete genome sequence of L. rhamnosus GG has been determined [22].
Hence, in the present study, we have isolated and sequenced 4 new L. rhamnosus strains from
blood cultures of bacteremic patients and performed genetic and phenotypic characterization
of these and 12 earlier described strains [23] collected during years 2005–2011 in Helsinki Uni-
versity Hospital laboratory (HUSLAB). First, we explored how different or similar these strains
are from the widely consumed probiotic strain L. rhamnosus GG at genomic level. Secondly,
we investigated the phenotypic features of these strains in vitro and compared them to L.
rhamnosus GG and selected Gram-positive pathogenic strains. Specifically, we examined their
ability to activate or inhibit complement system, induce platelet aggregation and form bio-
films. Finally, we investigated the possible associations between their phenotypic features and
surface proteins and exopolysaccharide associated proteins that are most likely to interact with
the environment and the host.
Our study revealed that all L. rhamnosus blood isolates were clearly different from L. rham-
nosus GG as well as each other at the genome level and clustered in two groups. All L. rhamno-
sus strains induced complement activation in serum when formation of C3a and TCC were
measured and none of them bound the complement inhibitors factor H (FH) and C4bp. Inter-
estingly, four out of 16 strains were able to induce platelet aggregation and one of those and
three other strains also formed a stronger biofilm compared to L. rhamnosus GG. Clear
Clinical blood isolate of L. rhamnosus
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differences were seen in the organization and the presence of genes encoding surface polysac-
charides, including EPS/capsular polysaccharide (CPS), between the clinical strains belonging
to the so-called cluster A and cluster B.
Materials and methods
Ethics statement
All persons who donated blood for this study provided a written informed consent. The study
protocol has been approved by the Academy of Finland (Projects 28 137389, 141140 and
1272870).
Bacterial isolates and growth conditions
Lactobacillus strains used in the study are listed in Table 1 and includes 4 newly sequenced
strains and 12 strains previously published [22, 23]. Clinical blood isolates of L. rhamnosus
strains were obtained from HUSLAB and collected from bacteremic patients between years
2005 and 2011. L. rhamnosus GG (ATCC 53103) was obtained from the Valio culture collec-
tion (Valio Ltd., Helsinki, Finland). L. salivarius CCUG 47825 was a kind gift from Prof. Paul
W. O’Toole (University College Cork, Cork, Ireland) [19]. Pathogenic control Streptococcus
pyogenes strain st369 was obtained from the collection of the National Institute for Health and
Welfare (Prof. Jaana Vuopio) and emm8 from ATCC (ATCC catalogue number 12349). S.
pyogenes strains were used as controls for complement activity and FH and C4bp binding
assays [24]. Lactobacilli were cultured at 37˚C in de Man-Rogosa-Sharpe (MRS) medium
(Difco BD, NJ, USA). S. pyogenes strains were grown at 37˚C with 5% CO2 on blood-agar
plates supplemented with colistin and oxolinic acid or in Todd-Hewitt broth (Difco BD, NJ,
USA). For in vitro assays Lactobacillus strains were cultured at 37˚C in MRS medium over-
night. The overnight bacterial cultures were diluted 1:100 and cultured until the OD600 reached
Table 1. Genetic information of L. rhamnosus strains isolated from blood cultures in HUSLAB, 2005–
2011.
Strain name Plasmid-matching* contigs G+C (%) ORFs
L. rhamnosus GG (ATCC 53103) 0 0 0
Lrh7 0 0 0
Lrh8 0 0 0
Lrh9 0 0 0
Lrh11 0 0 0
Lrh13 1 44.4 14
Lrh14 0 0 0
Lrh18 0 0 0
Lrh20 0 0 0
Lrh22 1 44.7 63
Lrh28 1 44.2 34
Lrh30 3 43.2 23
Lrh32 0 0 0
Lrh38 0 0 0
Lrh39 0 0 0
Lrh46 0 0 0
Lrh47 2 43.5 42
ORF indicates open reading frame.
https://doi.org/10.1371/journal.pone.0176739.t001
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0.5–0.7 for log phase and overnight for stationary phase. The cells were collected by centrifuga-
tion and glycerol was added until 20% to freeze the cultures. The strains were stored at -70˚C.
Genome sequencing
DNA was extracted from the bacterial cultures as described previously [23]. Libraries from
genomic DNA from L. rhamnosus strains were done for both 454 sequencing and MiSeq
sequencing following recommendation from respective manufacturer. The 454 libraries were
sequenced using a Genome Sequencer FLX (Roche) and titanium chemistry with read lengths
of ca 400 bp. The Illumina libraries were paired-end sequenced (250 bp + 250 bp) using a
MISeq (Illumina). All library preparations and sequencing were done at the DNA sequencing
and genomics laboratory, Institute Biotechnology, University of Helsinki, Finland. A com-
bined 454 and MiSeq read assembly were performed using the Celera Assembler v6.1 (http://
sourceforge.net/apps/mediawiki/wgs-assembler/index.php?title=Main_Page). Genomes were
annotated using the RAST server [25]. The new genome sequences were deposited to public
depository databases but most of them were published earlier by Ceapa et al. [23] or by others
(see for details Table 1).
Bioinformatics analysis
The orthology prediction was performed using sequence clustering and search program
Usearch v8.0.1623 [26]. To define orthologous groups, all the predicted ORF amino acid
sequences of all the strains were first ordered by length using the sortbylength command, and
then clustered with the cluster_smallmem command using identity threshold of 0.9. Thus, the
members of each ORF sequence cluster shared at least 90% amino acid identity over their
whole sequence lengths. The longest sequence in each cluster was chosen as the representative
sequence of that orthologous group. The pangenome was defined as the set of representative
sequences of the orthologous groups. The ortholog data was managed using R v. 3.2.2 (R) with
Biostrings library v. 2.40.2 [27] and in-house scripts. The ortholog copy number data was used
for hierarchical clustering of the strains by first removing orthologs that had variance <0.06
over the strains, and then calculating Euclidean distances between the strains and applying
Ward’s minimum variance method to the distances using R functions dist and hclust, respec-
tively. Clustering dendrograms were drawn with R library dendextend v. 1.3.0 [28], and the
function heatmap.2 from R library gplots v. 3.0.1. [29] was used for producing a row-wise cen-
tered and scaled heatmap of the filtered ortholog number matrix. Strains were compared at
nucleotide level to the L. rhamnosus GG genome using blastn program v. 2.2.31+ with parame-
ters -task magablast, -evalue 0.001 and -perc_identity 95. Mean similarity of aligned fragments
over 10 kb was calculated for each strain.
Complement activity determination using C3a and TCC ELISA
The frozen batches of log phase bacteria were used to activate complement in the serum pool
of healthy volunteers. Bacterial cells were washed with PBS and adjusted to have 107 bacterial
cells in 100 μl of PBS. The bacteria were mixed with the same volume of serum and incubated
for 30 minutes at 37˚C in agitation at 500 rpm. The reactions were stopped by adding EDTA
to a final concentration of 15 mM and by transferring the samples on ice. Cells were separated
from serum samples by centrifugation at 5,900g for 3 minutes and stored at -70˚C for C3a and
SC5b-9 (TCC) analysis. Complement C3a and SC5b-9 were analyzed from the samples using
the commercial MicroVue C3a EIA (Quidel, Tecomedical) and ELISA for TCC determination
as described earlier [30]. For C3a measurements serum samples were diluted 1 to 10,000 and
for TCC assay 1 to 2,000.
Clinical blood isolate of L. rhamnosus
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Direct 125I-factor H and C4bp binding assays
The binding of FH and C4bp were performed as described earlier [31]. Shortly, FH and C4bp
were labelled with iodine (125I; Perkin Elmer) using the Iodogen method [32]. The specific activ-
ities of the labelled proteins were 1–2 x 107 cpm/μg. Each bacterial strain (3 × 107 log phase bac-
teria/reaction) was incubated with 25,000 cpm of radiolabeled FH or C4bp in 100 μl of gelatin-
Veronal buffered saline for 30 minutes at 37˚C. The reaction mixtures were centrifuged (at
10,000g for 3 minutes) through 20% sucrose, and the radioactivity of each pellet and superna-
tant was measured with gamma counter. S. pyogenes strains were used as a negative (emm8)
and positive (st369) controls for FH binding and positive control for C4bp binding [33]. The
ratios of bound (pellet) to total activity (pellet + supernatant) were calculated as percentage.
Platelet preparation and aggregometry
Blood samples were collected from healthy donors as previously described [34]. Nine ml of
blood was collected into 3.2% Na-citrate tubes (Vacuette, ref. 455322, Greiner-bio-one) via
venipuncture from a cubital vein from a healthy donor using 20G needle. Whole blood was
centrifuged at 180g for 12 minutes at 22˚C without using brake. Platelet rich plasma (PRP) was
collected slowly above the buffy coat with a plastic Pasteur pipette into separate plastic tube.
The remaining blood was mixed and centrifuged again at 2,000g for 10 minutes at 22˚C to
obtain platelet poor plasma (PPP). The platelet count was measured with Sysmex XK-21 cell
counter and adjusted with PPP to the desired concentration.
Platelet aggregation was carried out in a profiler aggregometer (PAP-4, Bio/Data corp.),
with light transmission through PPP presenting 100% aggregation and that through PRP rep-
resenting 0% aggregation. PRP was used in a test well and the change in transmission over
time was a signal of the platelet aggregation. The frozen batches of bacterial cells were washed
with PBS three times. The final volume was adjusted to get 2 x 109 cfu/ml in PBS for platelet
aggregation experiments. Lactobacillus strains were determined for their ability to induce
platelet aggregation by the addition of 25 μl of a bacterial suspension to 475 μl of PRP. One
minute after agonist ADP or bacteria was added into the well the platelet response was moni-
tored for a maximum 30 minutes. Platelet viability was confirmed by addition to PRP of ago-
nist adenosine diphosphate (ADP) to a final concentration of 5 μM.
Biofilm assay
The microtiter plate biofilm assay is a static assay that has been used for examining biofilm for-
mation [35]. The wells of 24-well cell culture plate (Greiner Bio-One, Germany) were filled in
with serial dilution (1 to 10) of an overnight bacterial culture. After an incubation for 18 hour
at 37˚C, the wells were washed with aqua and stained with crystal violet. The crystal violet
stained plates were dried and scanned with Odyssey IR scanner (Licor) at 700 nm channel and
integrated intensities analyzed using Odyssey (v 2.1) analysis software. The bound dye was also
solubilized in 250 μl of 70% ethanol, transferred into 96-well plate and the optical density of
the ethanol-dye solution was determined at 600 nm using a microplate reader (Fluostar
Optima, BMG Labtech, Germany). The correlation between the methods was high (97.3%)
indicating that the crystal violet was a strong fluorophore at 700 nm and Odyssey scanner is a
useful tool for determining biofilms.
Western blot analysis of cell wall proteins
Cell wall proteins were extracted and the presence of SpaCBA and SpaFED pili were deter-
mined using Western Blot analysis as earlier described [22].
Clinical blood isolate of L. rhamnosus
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Statistical analysis
All values are presented as a mean ± SD. Where applicable, a 2-tailed Student’s t-test was used
to analyse the differences between groups (Excel software; Microsoft, Redmond, WA, USA).
Results
Genomic features and organization of L. rhamnosus clinical blood
isolates vs. L. rhamnosus GG
All L. rhamnosus strains described in the present study were isolated from clinical blood cul-
tures collected during 2005–2011 from the Helsinki University Hospital laboratory. The
genomes of four strains are reported here while that of the other 12 have been described earlier
[23]. Their general genomic information was compared to that of L. rhamnosus GG (Table 1
and Table 2). Genome size, G+C content and open reading frame (ORF) count of annotated
protein coding sequences varied greatly between the strains and differed from L. rhamnosus
GG. The genome sizes ranged from 2.86 to 3.17 Mb. The average genome size was 3.0
Mb ± 0.16 Mb which is in the same range as other members of the L. rhamnosus species [23].
The G+C content varied among the genomes from 46.6 to 46.8% being closely similar to L.
rhamnosus GG (46.7%) while the number of ORF predictions varied between 2648 and 3010,
exceeding that of L. rhamnosus GG (2926).
To analyze the similarity of the strains against L. rhamnosus GG at sequence level, a dendro-
gram based on cluster analysis of the presence of orthologs at 90% sequence identity was cre-
ated (Fig 1). This showed that the strains could be grouped into two main clusters and one
separate strain (Lrh20). It shows that the L. rhamnosus isolates are different from each other at
the sequence level and more remarkably, all are very different at the genomic level from L.
rhamnosus GG. The strains in cluster A have sequence similarity at nucleic acid level to L.
rhamnosus GG between 99.942 and 99.984% whereas the strains in cluster B differ remarkably
Table 2. Plasmids of the L. rhamnosus strains.
Strain name Plasmid-matching*contigs G+C (%) ORFs
L. rhamnosus GG (ATCC 53103) 0 0 0
Lrh7 0 0 0
Lrh8 0 0 0
Lrh9 0 0 0
Lrh11 0 0 0
Lrh13 1 44.4 14
Lrh14 0 0 0
Lrh18 0 0 0
Lrh20 0 0 0
Lrh22 1 44.7 63
Lrh28 1 44.2 34
Lrh30 3 43.2 23
Lrh32 0 0 0
Lrh38 0 0 0
Lrh39 0 0 0
Lrh46 0 0 0
Lrh47 2 43.5 42
* indicates BLASTN e-value < 0.000001, identity > 85%, alignment length > 5kb; ORF indicates open reading frame
https://doi.org/10.1371/journal.pone.0176739.t002
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more having the similarity between 97.0 and 98.5% (Fig 1). Interestingly, all the genomes of
five isolated L. rhamnosus strains (Lrh13, Lrh22, Lrh28, Lrh30 and Lrh47) that contain plas-
mids belong to the cluster B (Table 2, Fig 1). The presence of unique orthologs between clus-
ters were compared (S1 Table). Most of the differing orthologs that could be annotated, and
are not phage sequences, are exopolysaccharide-related. Cluster A consists of 66 orthologs that
were not found from cluster B and 35 orthologs that were missing from cluster A but present
in cluster B. Interestingly, there were 8 EPS related ORFs present and 10 absent in cluster A.
Complement activation and binding of complement regulators
The recovery of L. rhamnosus isolates from the blood of bacteremic patients raised questions
about their survival within the human bloodstream and also their (possible) recognition or
killing by the host immunological system. Initial experiments indicated L. rhamnosus GG and
clinical isolates showed only little survival in blood (less than 31% survival after 3 hours at
37˚C) in contrast to strain st369, a known pathogen belonging to the Group A Streptococci,
which multiplies rapidly in blood (at least 5 cell divisions after 3 hours at 37˚C; see S2 Table).
To further explore these, we studied in vitro if the isolated strains can activate the complement
system and thus, be recognized by the human innate immune system, and if they are able to
bind complement regulators to evade complement in the manner of pathogenic bacteria.
Fig 1. Clustering analysis of strains by ortholog copy numbers. The heat map rows represent centered
and scaled ortholog copy numbers found in the strains. The dendrogram on the columns shows hierarchical
clustering of the strains based on their ortholog copy numbers. Columns are annotated by each strain’s
BLAST nucleotide similarity to the L. rhamnosus GG genome.
https://doi.org/10.1371/journal.pone.0176739.g001
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Strains were incubated with human serum to trigger the complement activation response. All
the isolates as well as L. rhamnosus GG induced the formation of C3a and soluble terminal
component TCC in serum (Fig 2 and S3 Table). All tested L. rhamnosus strains induced signif-
icantly higher C3a concentrations in serum than the negative control (S. pyogenes st369). Simi-
lar observations were made for the levels of TCC, although more variations were seen among
isolates (notably between Lrh14 (the lowest) and Lrh7, Lrh13, Lrh18, Lrh20 and Lrh30 (the
highest values)). Taken together, the amounts of both complement activity markers (C3a and
TCC), indicated that the complement system was activated in the presence of the isolated L.
rhamnosus strains in vitro, as opposed to the S. pyogenes st369, which did not activate the com-
plement system similarly as earlier described [24].
To further explore additional factors mediating activation of the complement and to assess
the ability of these strains to potentially inhibit complement activation, we examined the direct
binding of complement regulators FH and C4bp to all L. rhamnosus strains (Fig 2, S3 Table).
No binding of FH or C4bp to any of the L. rhamnosus strains was observed. The FH binding
ranged between 0.3–0.55% and the C4bp binding between 1.6–5.8%, which corresponds to
background levels (0.40 ± 0.15% and 3.1 ± 0.6%, respectively). In contrast, the control strain S.
pyogenes st369 showed strong FH binding (46.7 ± 14.1%) and both S. pyogenes emm8 (35.7 ±
0.2%) and st369 (31.9 ± 14.7%) exhibited strong C4bp binding as previously reported [33].
These results indicate that the L. rhamnosus blood isolates and the probiotic strain GG do not
bind these complement regulators and therefore do not escape complement using studied
mechanisms as known in pathogens [38, 39].
Fig 2. A heatmap of phenotypic features of the L. rhamnosus strains measured in vitro. Combined data represent average values or numbers of the
strains detected in clusters A and B. NC equals negative control containing buffer in the assays, GAS group A streptococcus, NT not tested, asterisk* equals
values that are representative from literature but not tested here for platelet aggregation [36] and biofilm formation [37], TCC equals terminal complement
complex, FH factor H, C4bp complement C4b binding protein, CBA SpaC, SpaB and SpaA pilin subunits and fibron. bp equals fibronectin/fibrinogen binding
protein. Bold and Italic letters equal significant value, p<0.05 for biofilm formation compared to L. rhamnosus GG (GG). Color intensities indicate the level
of the values: green for complement activation measured as C3a and TCC, red for binding of complement regulators, blue for platelet aggregation, purple for
biofilm formation and light green express the presence of SpaCBA pilus determined by Western blot using anti-SpaA antibody and fibronectin/fibrinogen
binding protein at genome.
https://doi.org/10.1371/journal.pone.0176739.g002
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Human platelet aggregation by the L. rhamnosus strains
Next we studied the capacity of the L. rhamnosus strains to promote platelet aggregation. Plate-
lets are cell fragments that plug the leakage in a damaged blood vessel but they are also key
components in the innate immune system [40]. Many Gram-positive bacteria causing sepsis
have been shown to induce platelet aggregation [41]. The L. rhamnosus strains were tested for
platelet aggregation using isolated platelets from different human donors (Fig 2, S3 Table).
Four out of 16 L. rhamnosus isolates (Lrh11, Lrh18, Lrh22, Lrh28) induced platelet aggrega-
tion. It is noteworthy that platelet aggregation was donor-dependent. Hence the same strain
did not always induce platelet aggregation for every donor tested and this was also noted for
the positive control L. salivarius CCUG 47825 (S3 Table). Two of the aggregating strains,
Lrh22 and Lrh28, induced platelet aggregation with platelets from every donor tested. Similar
to previous studies [17] L. rhamnosus GG and the rest of the twelve isolates did not induce
platelet aggregation for any tested donors. The experimental data shown here suggest that the
L. rhamnosus blood isolates differ in their ability to cause platelet aggregation and that platelet
aggregation was not a common phenotypic trait associated with L. rhamnosus blood isolates
although 2 clinical strains were highly proficient platelet aggregators.
Biofilm formation by the L. rhamnosus strains
Biofilm formation is a feature found in both pathogenic and commensal bacteria, as it pro-
motes colonization and persistence in an ecological habitat. Hence, we assessed the formation
of biofilms for L. rhamnosus strains in 24-well plates (Fig 2 and S3 Table). Some differences in
biofilm formation could be seen between the isolated strains. Four of the strains (from cluster
B) tested (Lrh13 (8.9 ± 3.1%), Lrh28 (13.1 ± 4.7%), Lrh30 (7.1 ± 2.3%), Lrh32 (5.4 ± 1.3%))
showed a stronger ability for biofilm formation than GG (3.8 ± 0.8%). L. salivarius CCUG
47825 was used as a positive control and produced a strong biofilm (relative biofilm formation
100 ± 25.7%). Summarizing, biofilm formation varied between L. rhamnosus isolates with
some strains displaying higher biofilm formation than L. rhamnosus GG. All those strains that
showed clear biofilm formation phenotype belong to cluster B.
Comparison of LPXTG protein encoding genes, SpaCBA pilus proteins
and EPS related genes
In an attempt to further characterize the phenotypes of these different isolate, we examined
some of the relevant genomic features related to surface exposed structures and molecules of
these strains. Typically, the genomes of Gram-positive bacteria harbor genes that code for
LPXTG proteins as well as the sortase enzymes. Sortases are involved in the surface display
and cell wall anchoring of surface proteins carrying the sortase-specific recognition motif
LPXTG in Gram-positive bacteria [42]. Based on the genome sequences of the blood isolates,
we investigated the repertoire of all gene sequences that are predicted to code for LPXTG pro-
teins, as they are most likely to interact with the environment and the host, in that particular
context with the human vascular system. All strains possessed a distinct and unique set of pro-
teins (S2 Fig). It has been well established that the presence of pili depends on a specific set of
LPXTG proteins that include major pilin, minor pilin and, tip pilin subunit proteins and these
are widely spread in various Lactobacillus spp. [2]. In L. rhamnosus GG, two pili gene clusters
have been identified but only SpaCBA pili have been found to be produced [22, 43]. Hence, we
used Western blot analysis with SpaA and SpaD antibodies to show that 8 out of 16 L. rhamno-
sus strains produced SpaCBA pili while none were producing the SpaFED pili (Fig 2) even
though the SpaFED locus was found in all strains (S1 Fig). Five of these showed phenotypic
Clinical blood isolate of L. rhamnosus
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characters (platelet aggregation (Lrh18, Lrh11) or biofilm formation (Lrh13, Lrh30) or both
(Lrh28; Fig 2)). When the strains were divided into two groups based on the presence of
SpaCBA pilus there was a significant association between the biofilm formation and the pres-
ence of pilus among the isolated strains (6.5 ± 3.11% (present) vs 3.87 ± 0.72% (absent),
p = 0.047, S3 Table).
As the surface polysaccharides are known to participate in important functions during path-
ogenesis, such as tissue adherence, biofilm formation and evasion of host defence [44, 45] and
our clusters of L. rhamnosus strains showed differences between the ORFs related to EPS/CPS
gene clusters (S1 Table), we wanted to study if the genomic organization of EPS gene clusters in
the studied blood isolates of L. rhamnosus are similar to L. rhamnosus GG [46]. This cluster con-
sists of genes coding proteins for the regulation of EPS production and polymerization (wzd,
wze, wzr, wzb), polysaccharide transportation and polymerization (wzx, wzy), glycosyltrans-
ferases (welJ, welI, welH, welG, welF, welE), biosynthesis of the dTDP-rhamnose precursor
(rmlA, rmlC, rmlB) and UDP-galactopyranose mutase for biosynthesis of the sugar nucleotide
precursor for galactofuranose (glf) [46]. Interestingly, after annotation analysis our data showed
that the strains in cluster A had the EPS cluster consisting 16 putative ORFs/genes with similar
identity (> 78%) to those present in L. rhamnosus GG (Fig 3A). However, the strains in cluster
B had only some of these genes (wzd, wze, wzr, wzb and rmlB (except Lrh22)) with similar iden-
tity (> 78%) to genes in EPS cluster of L. rhamnosus GG (Fig 3B). The other genes found in this
cluster were annotated to encode genes for mostly glycosyl transferases with different specifici-
ties, hypothetical proteins and several mobile element proteins. However, we were not able to
characterize these clusters in details because multiple mobile elements were present and they
spliced the sequences into multiple contigs. Interestingly, the strains in cluster B consist also a
different type of polysaccharide (EPS/CPS) cluster comprising of 19 genes (Fig 3B) including an
additional flippase (6.) gene essential for EPS production. The cluster was similar in most of the
strains (Lrh22, Lrh30, Lrh32 and Lrh47) in the cluster B (Fig 3B). The strain Lrh11 had a mobile
element in the PS cluster before the gene coding for lysozyme and the strains Lrh13 and Lrh28
had two point mutations within the lysozyme gene (resulting in a split gene). The differences in
the organization and existence of the polysaccharide clusters may have an influence on the poly-
saccharide surface of the strains and could potentially lead differences in the phenotype of these
isolates.
Discussion
Although Lactobacillus spp. are commensals, part of the normal flora of the gastrointestinal
tract, oral cavity and female urogenital tract [47], they have been occasionally isolated from
immunocompromised and other hospitalized patients [6]. In the present study, we have iso-
lated and sequenced 4 new strains and 12 already described L. rhamnosus strains from blood
cultures collected from bacteremic patients between years 2005 and 2011 in HUSLAB. The
main purpose of this study was to first identify the isolated strains at the sequence level and
compare them to the widely consumed probiotic L. rhamnosus GG and, secondly, to investi-
gate the phenotypic features related to complement evasion, platelet aggregation and biofilm
formation in these isolated L. rhamnosus strains and compare these characteristics with L.
rhamnosus GG. Our data revealed that L. rhamnosus isolates were clearly different from L.
rhamnosus GG and each other at sequence level and they did not possess any distinctive niche
specific (blood) genotypic traits as compared to L. rhamnosus GG. The strains were clustered
into two main clusters A and B. Cluster A includes L. rhamnosus GG and its related strains. A
model summarizing our findings (Fig 4) shows that all the isolated L. rhamnosus strains,
including L. rhamnosus GG, were able to activate the complement system when it was
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measured as C3a and TCC formation in serum. Similarly, the strains did not bind complement
inhibitors C4bp or FH. These results indicate that L. rhamnosus strains have not acquired
mechanisms or traits to escape the complement system as opposed to the tested pathogens.
However, some differences were seen in other phenotypic features, since four of the sixteen
strains induced platelet aggregation and four strains formed stronger biofilm compared to L.
rhamnosus GG. Most of these strains belong to the cluster B. The L. rhamnosus blood isolates
showed a high level of heterogeneity and showed no common phenotypic trait that is involved
in the persistence in the host, like biofilm formation, platelet aggregation and specific pilus
production. Interestingly, analysis of genes encoding polysaccharide clusters showed differ-
ences between the strains in cluster A and B that might be also influencing the differences seen
in phenotypes.
Fig 3. Genomic organization of polysaccharide clusters in L. rhamnosus strains. A) EPS gene cluster of L. rhamnosus GG is found from L. rhamnosus
strains of cluster A and strain Lrh20. Insertion sequence (IS)-like elements differ between the strains. B) The L. rhamnosus strains of cluster B have differences at
sequences encoding genes in the EPS gene cluster compared to L. rhamnosus GG. The genes similar to the EPS gene cluster of L. rhamnosus GG are named in
the schematic illustration in the upper part (B). These regions include multiple genes coding IS-like elements such as IS5, IS66 and DDE transposases in the
cluster B. The strains in cluster B have also other type of EPS/CPS gene cluster based on BLAST annotation results shown at the bottom (B). It consists of 19 or 20
genes which are annotated as 1. peptidoglycan N-acetylglucosamine deacetylase (EC 3.5.1.104), 2. hypothetical protein (FIG00750667), 3. capsular polysac-
charide biosynthesis protein, 4. hypothetical protein (FIG00754398), 5. tyrosine-protein kinase transmembrane modulator EpsC, 6. putative O-unit flippase, 7.
glycosyl transferase, group 0, 8. glycosyl transferase family protein, 9. hypothetical protein (FIG00752018), 10. mobile element protein, 11. lysozyme M1 (1,4-beta-
N-acetylmuramidase), 12. hypothetical protein (FIG00747485), 13. uncharacterized conserved protein, similar to IcaC of Staphylococcus; YHJR B.subtilis family,
14. glycosyltransferase, 15. UDP-N-acetylglucosamine 2-epimerase (EC 5.1.3.14), 16. hypothetical protein (FIG00750997), 17. lipopolysaccharide synthesis
sugar transferase, 18. polysaccharide biosynthesis protein CpsM, 19. putative N-acetylgalactosaminyldiphosphoundecaprenol and 20. UDP-glucose 4-epimerase
(EC 5.1.3.2). * = Transposase, IS150/IS3 present (only in Lrh11), " = site of point mutations in the gene encoding lysozyme M1(1,4-beta-N-acetylmuramidase)
(present in Lrh13 and Lrh28). The illustration of EPS cluster in 3A is modified after [46].
https://doi.org/10.1371/journal.pone.0176739.g003
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Our results of the current study extend the results of the earlier survey by Salminen and co-
workers [48] and unambiguously demonstrate that the widely consumed L. rhamnosus GG
was not associated with the bacteremia cases. The techniques used for the analysis of the strains
at sequence level have been highly improved from earlier used PFGE method to full genome
Fig 4. Immunological properties of L. rhamnosus GG, clinical isolates and pathogens towards the human host based on in vitro data. Strains
Lrh7, Lrh8, Lrh9, Lrh14, Lrh20, Lrh46, Lrh47, Lrh38 and Lrh39 displayed comparable properties as observed in L. rhamnosus GG. All these strains activate
the complement in serum. Strains Lrh13, Lrh30 and Lrh32 also induced more biofilm formation more than GG. Strains Lrh11, Lrh18 and Lrh22 were
aggregating with platelets. Strain Lrh28 was doing both causing platelet aggregation and biofilm formation. The pathogenic group A Streptococcus strain
emm8 induced complement activation, but it could bind complement regulator C4bp to evade complement. The pathogenic strain st369 could bind
complement regulators C4bp and factor H and did not induce complement activation. A similar type of GAS strain has been shown to cause platelet
aggregation [36] and biofilm formation [37]. The bolded strains have SpaCBA pili similar to GG.
https://doi.org/10.1371/journal.pone.0176739.g004
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sequence analyses up to 100% coverage of the sequence that allow to distinguish the strains at
species level. However, there are reports that some cases of bacteremia have been associated
with the consumption of probiotics among certain special conditions including hematopoietic
stem cell transplantation [49], HIV-infection [50], severe active ulcerative colitis [13] and in a
newborn with intrauterine growth restriction [51]. However, not all studies have determined
the strains at species level. Only Sadowska-Krawczenko (2014) analyzed the identity at 100%
(16S sequencing and PCR) in the case of intrauterine growth restriction [51]. A case report
demonstrates that it is important to use the molecular diagnostic tools that can distinguish the
strains at species level when we want study if the blood isolate originates from the probiotic
strain consumed [52]. It is known earlier that immuno-compromised patients and patients with
underlying diseases such as cancer are the ones who usually suffer from bacteremia caused by
lactobacillus [48, 53]. Based on our and others’ studies we conclude that healthy people can use
probiotics safely but among risk patients having disturbed immune function and mucosal dis-
ruption as in the case of inflammatory bowel diseases, the consumption of probiotics should be
considered with caution before new studies have carefully assessed the risk to these patients.
All the Lactobacillus strains were recognized by the complement system and had no proper-
ties to inhibit the complement system by binding complement regulators (C4bp or FH). Thus,
in this respect they can be categorized as commensals in contrast to pathogenic GAS strains
emm8 and st369 that we used in this and an earlier study [24]. However, some variation in the
level of TCC formation between the strains could be seen. Recently, piliation of L. rhamnosus
GG has been shown to bind macrophages through a pattern recognition receptor namely com-
plement receptor type 3 (CR3, iC3b receptor, CD11b/18) that mediates phagocytosis and
removal of bacteria [54]. The SpaCBA piliation was also analyzed in the current study (Fig 2).
The group having pili showed to have only a borderline increase in the complement TCC level
(483.9 ± 76.4 AU/ml and 407.3 ± 68.1 AU/ml, p = 0.053; S2 Table) compared to the group
without the SpaCBA pili. However, when the difference in complement activation as TCC
between the SpaCBA pilus-deficient mutant strain of L. rhamnosus (PB12) [55] and L. rhamno-
sus GG was tested no significant difference was seen (441.5 ± 78.4 AU/ml vs 398.4 ± 87.1 AU/
ml, p = 0.07, respectively). Both of these strains induced similarly TCC formation in serum
indicating that pilus as a structure is not inducing more complement activation. Thus, our
data suggest that the isolated strains are recognized by the complement and they do not differ
from each other in the ability to induce complement activation in serum and have not devel-
oped properties similar to pathogens.
Moreover, in our study we demonstrated that some of the strains have phenotypic features
that are different from L. rhamnosus GG but can be found from pathogenic strains. These phe-
notypic features were abilities to cause platelet aggregation and biofilm formation. Earlier
studies with a handful of strains have also shown that some of the clinical isolates of L. rhamno-
sus have been able to cause platelet aggregation [16, 18]. Those strains were isolated from infec-
tious endocarditis (5/5 tested strains), laboratory strains (8/16 strains) [15] and strains from
infection of aortic aneurysm graft and carcinoma with liver metastasis [18]. Similar to our
findings, L. rhamnosus GG did not cause aggregation with platelets in previous studies [17,
18]. The ability to bind fibrinogen is known to help Gram-positive pathogens escape the
immune system, and can be sufficient to induce platelet aggregation which can lead to e.g.
endocarditis [41]. Recently a L. salivarius isolate from a case of sepsis, was found to aggregate
human platelets via binding human fibrinogen through a novel fibrinogen-binding protein
[19]. In our study a gene encoding fibrinogen/fibronectin binding proteins was present but we
could not show that it causes the platelet aggregation phenotype (Fig 3).
We found that five of the isolated L. rhamnosus strains (Lrh28, Lrh13, Lrh30, Lrh32) were
able to form biofilm more than L. rhamnosus GG (Fig 2). Interestingly, one strain (Lrh28) had
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the platelet aggregation phenotype, as well. Biofilms of lactobacilli can be located in many nat-
ural environments. Pathogenic bacteria can utilize the biofilm formation capacity for better
survival in human body [56]. Various genetic pathways including clusters producing surface
polysaccharides (EPS) have been shown to influence the biofilm formation capacity of L.
rhamnosus GG in an earlier study [46]. Similar to a previous study we found in our experi-
ments that L. rhamnosus GG was able to form small amounts of biofilms in the MRS medium
[57]. Interestingly, we found that the strains in cluster A and cluster B possessed different EPS
clusters so that the strains in cluster A had the EPS cluster similar to L. rhamnosus GG but the
strains in cluster B had different sets of genes encoding proteins needed for EPS/CPS produc-
tion such as glycosyltransferases and hypothetical proteins than GG. They also had an addi-
tional polysaccharide cluster that was found from all those strains in cluster B. However, one
of the limitations of our study is that the genomic sequences of the isolated L.rhamnosus strains
were not complete and contained some gaps. Moreover, we did not compare the gene expres-
sion of the L. rhamnosus strains and hence could not correlate all our functional analyses to
the gene level. At least partly some of the phenotypic features could be caused by differences in
the organization of EPS/CPS clusters. Recently, it has been shown that alterations in the genes
involved in EPS synthesis in Lactobacillus johnsonii changed their surface properties and influ-
enced on biofilm formation, cell adhesion, and autoaggregation [58]. Two clinical L. rhamno-
sus strains isolated from dental pulp infections have been shown to have modified
exopolysaccharide clusters [21]. Such a biofilm producing phenotype can provoke the develop-
ment of infections e.g. in the case of dental pulps, during catheter usage or endocarditis and be
detrimental to a patient during bacteremia. However, biofilm formation is usually a feature
associated with niche colonization in a different context than in clinical cases.
To conclude, our data demonstrate that L. rhamnosus strains isolated from blood cultures
are distinct from L. rhamnosus GG and well-recognized by the body through the complement
system and differ clearly from pathogenic strains. This supports the safe use of L. rhamnosus
GG in healthy subjects with a functional immune system. Clinical blood isolates of L. rhamno-
sus do not possess any distinctive niche-specific genotypic traits for the blood environment
similar to pathogens, which may be explained by the fact that they resided for a short period of
time in blood and originally derived from other niches such as mouth, vagina, intestine or
food products. In that regard, some of the strains that have platelet aggregation and biofilm
formation properties might originate from those types of niches, where these properties are
central for the stability and vitality of the strain.
Supporting information
S1 Table. Orthologs uniquely present and absent in Cluster A compared to Cluster B.
(XLS)
S2 Table. Blood survival assay. Experiments showing the survival of strains L. rhamnosus GG,
clinical blood isolate of L. rhamnosus and st369 a group A streptococcus in blood.
(XLSX)
S3 Table. The original data for phenotypic features of the L. rhamnosus strains measured
in vitro. The data consist of complement C3a and TCC formation after stimulation with the
strains, the binding of complement inhibitors factor H and C4bp and determination of platelet
aggregation and biofilm formation.
(XLSX)
S1 Fig. Western blots of the cell wall protein extracts detected with SpaA or SpaD antibod-
ies. Polyclonal (Rabbit) anti-SpaA and anti-SpaD were used as 1:10000 dilution. Molecular
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masses (kDa) of the standard proteins are depicted on the left side of the blots. Lr GG equals L.
rhamnosus GG. The methods are described in detail [22].
(PDF)
S2 Fig. LPXTG genes ordered based on a dendrogram illustrating the phylogeny of Lacto-
bacillus rhamnosus strains. Platelet aggregation and biofilm formation data (similar to Fig 2)
are shown. LPXTG genes were searched based on the known LPXTG sequences shown. Six of
them were present only in cluster B.
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